Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
This study is being done to examine the usefulness of Positron Emission Tomography (PET) imaging with florbetapir F 18 as a biomarker in the identification of amyloid-ß peptide (Aß) in the brain. Amyloid-ß peptide (Aß) accumulates in the brains of patients with Alzheimer's disease. Florbetapir F 18 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera. The development of biomarker and imaging studies that track the development of PPA and reflect the change in people's bodies may help other people who have a similar medical problem in the future.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who, in the opinion of the investigator, can tolerate the PET scan procedures
You may not be if
Clinically significant cardiovascular disease
clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
Pregnant
Breastfeeding
Women of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.
History of relevant severe drug allergy or hypersensitivity
Patients who have received an investigational medication under an FDA Investigational New Drug (IND) protocol within the last 30 days.
